Education
About Us
Working with TipRanks
Follow Us
STXI - ETF AI Analysis
Top Page
Strive International Developed Markets ETF (STXI)
Rating:68Neutral
Price Target:―
Positive Factors
Strong Top Holdings
Several of the ETF's largest positions, including ASML Holding NV and Nestlé SA, have delivered strong year-to-date performance, supporting overall returns.
Global Diversification
The ETF offers exposure to a wide range of countries, including Japan, the UK, and France, reducing reliance on any single geographic market.
Reasonable Expense Ratio
With a relatively low expense ratio of 0.29%, the fund is cost-effective compared to many international ETFs.
Negative Factors
Sector Concentration in Financials
The ETF has a heavy allocation to financials at over 27%, which could increase vulnerability to sector-specific risks.
Underperforming Holding
SAP SE, one of the top holdings, has shown negative year-to-date performance, potentially dragging on the fund's overall returns.
Limited U.S. Exposure
The ETF has only 13% exposure to U.S. companies, which may limit participation in the strong performance of the U.S. market.
STXI vs. SPDR S&P 500 ETF (SPY)
AUM21.35M
RegionDeveloped Markets
Expense Ratio0.29%
Beta0.72
IssuerStrive
Inception DateJun 26, 2024
Dividend Yield2.21%
Asset ClassEquity
Index TrackedBloomberg Developed Markets ex US Large & Mid Cap Index - Benchmark TR Net
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume1,061
30 Day Avg. Volume2,330
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
33.48Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering250
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
STXI Summary
The Strive International Developed Markets ETF (STXI) is an investment fund that focuses on stocks from developed countries outside the United States. It includes companies from industries like finance, technology, and healthcare, with top holdings such as Nestlé and AstraZeneca. This ETF is designed for investors who want to diversify their portfolio globally and benefit from the growth of established international markets. However, since it tracks the overall performance of developed markets, its value can rise or fall depending on global economic conditions.
How much will it cost me?The Strive International Developed Markets ETF (STXI) has an expense ratio of 0.29%, which means you’ll pay $2.90 per year for every $1,000 invested. This cost is slightly higher than average for ETFs because it is passively managed but focuses on a broad international market niche, which can involve additional complexities compared to U.S.-focused funds.
What would affect this ETF?The Strive International Developed Markets ETF (STXI) could benefit from economic growth in developed markets outside the U.S., particularly if sectors like financials, technology, and healthcare continue to innovate and expand. However, challenges such as rising interest rates, geopolitical tensions, or regulatory changes in key regions could negatively impact its performance, especially for top holdings like ASML, Nestlé, and HSBC that are sensitive to global economic conditions.
STXI Top 10 Holdings
The Strive International Developed Markets ETF (STXI) leans heavily into financials, with names like HSBC and Royal Bank of Canada providing steady growth and attractive dividends that buoy the fund’s performance. Health care giants Roche and AstraZeneca are also rising stars, benefiting from robust pipelines and strategic market expansions. However, tech holdings like SAP and Siemens have been lagging, with bearish momentum weighing on returns. While the fund’s broad exposure across developed markets offers diversification, its concentration in financials and industrials means sector-specific trends could significantly impact future performance.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 2.39% | $512.60K | €345.09B | 37.21% | 76 Outperform | |
| AstraZeneca | 1.64% | $351.82K | £216.63B | 31.68% | 78 Outperform | |
| Roche Holding AG | 1.60% | $343.34K | CHF246.07B | 33.03% | 73 Outperform | |
| Novartis AG | 1.51% | $323.55K | CHF198.85B | 12.02% | 80 Outperform | |
| SAP SE | 1.48% | $317.98K | €243.40B | -7.27% | 66 Neutral | |
| HSBC Holdings | 1.47% | $314.70K | £183.81B | 45.03% | 79 Outperform | |
| Nestlé SA | 1.47% | $314.71K | CHF201.76B | 14.02% | 71 Outperform | |
| Royal Bank Of Canada | 1.29% | $277.16K | $217.35B | 22.61% | 75 Outperform | |
| Shell (UK) | 1.29% | $276.56K | £159.39B | 9.95% | 74 Outperform | |
| Siemens | 1.25% | $268.62K | €178.80B | 25.05% | 74 Outperform |
STXI Technical Analysis
Positive
―
Price Trends
30.26
Positive
29.64
Positive
28.17
Positive
Market Momentum
<0.01
Negative
51.92
Neutral
89.89
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For STXI, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 30.30, equal to the 50-day MA of 30.26, and equal to the 200-day MA of 28.17, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 51.92 is Neutral, neither overbought nor oversold. The STOCH value of 89.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STXI.
STXI Peer Comparison
Comparison Results
Performance Comparison
STXI
Strive International Developed Markets ETF
30.38
5.31
21.18%
QLVD
FlexShares Developed Markets ex-US Quality Low Volatility Index Fund
―
―
―
DEEF
Xtrackers FTSE Developed ex US Multifactor ETF
―
―
―
INEQ
Columbia International Equity Income Etf
―
―
―
OEFA
O'Shares International Developed Quality Dividend ETF
―
―
―
FFDI
Fidelity Fundamental Developed International ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents